Progyny, Inc. announced strong financial results for the second quarter of 2025, with record revenue of $332.9 million, a 9.5% increase year-over-year. The company also reported significant growth in gross profit and net income, alongside robust operating cash flow. This performance was primarily attributed to increased member engagement and an expanded client base.

Progyny reported a strong start to 2025 with record first-quarter revenue of $324.0 million, a 16.5% increase year-over-year. The growth was primarily driven by an increase in clients and covered lives. The company also raised its full-year guidance.

Progyny, Inc. announced robust financial results for the fourth quarter of 2024, with revenue reaching $298.4 million, a 10.6% increase year-over-year. The company achieved a net income of $10.5 million and Adjusted EBITDA of $47.5 million, reflecting strong operational performance. Full year 2024 revenue increased by 7.2% to $1,167.2 million, with record Adjusted EBITDA of $198.8 million.

Progyny reported a 2.0% increase in revenue for the third quarter of 2024, reaching $286.6 million. The company added over 80 new clients and secured a leading national health plan and a regional health plan as preferred partners. However, utilization patterns affected revenue and profitability.

Progyny reported an 8.8% increase in revenue, reaching $304.1 million, driven by growth in clients and covered lives. The company achieved record quarterly Adjusted EBITDA of $54.5 million, a 15% increase year-over-year. Net income rose to $16.5 million, or $0.17 per diluted share.

Progyny's Q1 2024 revenue increased by 7.6% to $278.1 million, driven by growth in clients and covered lives. Net income was $16.9 million, or $0.17 per diluted share. The company repurchased 723,577 shares for $26.4 million during the quarter.

Progyny's Q4 2023 saw a 26% increase in revenue, gross margin expansion by 30 basis points, and a near quadrupling of net income. The company exceeded $1 billion in annual revenue for the first time in 2023, with cash flow from operations more than doubling.

Progyny reported record quarterly revenue of $280.9 million, a 37% increase year-over-year. The company also raised its full-year revenue and earnings guidance, driven by a strong sales season that added 1.3 million new covered lives. Adjusted EBITDA increased by 43%, reflecting the company's ability to scale operations effectively.

Progyny, Inc. reported a record quarterly revenue of $279.4 million, a 43% increase compared to the prior year period. The company achieved a record quarterly operating cash flow of $76.0 million and raised its full-year revenue and earnings guidance, reflecting strong employer demand for fertility and family-building solutions.

Progyny announced strong first quarter 2023 results, with record quarterly revenue of $258.4 million, a 50% increase over the prior year period. The company also raised its full year revenue and earnings guidance, driven by healthy demand for family building solutions and new partnerships.

Progyny reported a strong fourth quarter in 2022, with revenue growing 68% over the prior year period and a record $51.5 million in operating cash flow. The company's client base has become more diverse, and they anticipate crossing the $1 billion revenue milestone in 2023.

Progyny's Q3 2022 revenue grew by 68% year-over-year to $205.4 million, driven by healthy utilization and a successful selling season, resulting in a record 105 new client commitments expected to add approximately 1.2 million covered lives. Adjusted EBITDA more than doubled, and the company raised its full-year 2022 guidance.

Progyny reported a strong second quarter with a 52% increase in revenue compared to the prior year, reaching $195.0 million. The company saw growth in both fertility and pharmacy benefit services, and raised the lower end of its full-year guidance range.

Progyny's Q1 2022 results showed a strong start to the year with record revenue of $172.2 million, a 41% increase year-over-year. The company also reported growth in gross profit and Adjusted EBITDA, driven by higher revenue and operational efficiencies. They are raising the lower end of full year 2022 guidance ranges.

Progyny reported a 24% increase in revenue, reaching $122.3 million for the third quarter of 2021. The company added more than 85 new clients, representing approximately 1.2 million new covered lives for 2022. Margins expanded significantly, and the company generated substantial operating cash flow.

Progyny reported a record second-quarter revenue of $128.7 million, reflecting a 99% increase compared to the previous year. The company's net income was $18.7 million, or $0.19 per diluted share, a significant increase from the net loss of $1.1 million in the second quarter of 2020. The company had 182 clients as of June 30, 2021, as compared to 134 clients as of June 30, 2020.

Progyny reported a record first quarter revenue of $122.1 million, a 51% increase compared to the first quarter of 2020. Net income increased by 318% to $15.2 million, or $0.15 income per diluted share. The company issued revenue guidance of $126.0 to $131.0 million for the second quarter of 2021, reflecting growth of 95% to 103%.

Progyny reported a strong fourth quarter with revenue exceeding $100 million for the first time. The company successfully managed the impacts of the COVID-19 pandemic, achieving record levels of revenue, profitability, and operating cash flow.

Progyny announced a record third quarter revenue of $98.9 million, a 62% increase compared to the prior year period. The company also raised revenue guidance to $340.0 to $345.0 million for full year 2020, reflecting growth of 48% to 50%, and affirmed preliminary view of a minimum of $525 million in 2021 revenue.

Progyny, Inc. reported a 15% increase in revenue for the second quarter of 2020, despite the negative impact of COVID-19 on treatment volumes. The company's revenue reached $64.6 million, driven by growth in both fertility and pharmacy benefit services. While the company experienced a net loss of $1.8 million, patient return to treatment was faster than expected, and the company issued revenue guidance of $323.0 to $340.0 million for the full year 2020.